Get 50% OFF This Summer!

Advertisement
logo

Piramal Pharma

PPLPHARMA
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Piramal Pharma Share price and Fundamental Analysis

View All Details
View All Details
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.
Company Incorporation2020
ChairmanNandini Piramal
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
27,177
PE Ratio
297.1
Industry P/E
35.07
PEG Ratio
0.72
ROE
1.12%
ROCE
6.36%
ROA
0.58%
Total Debt (Cr)
1,243.18
Debt to Equity
0.6
Dividend Yield
0.07%
EPS
0.69
Book Value & P/B
56.22 x 3.65
Face Value
10
Outstanding Shares(Cr)
132.57
Current Ratio
2.61
EV to Sales
3.45

Included In

+More

Stock Returns

1 Week+1.26%
1 Month-5.96%
6 Months-17.14%
1 Year+39.21%
3 Years+12.43%
5 Years+12.43%

CAGR

1 Year CAGR

Revenue Growth

+15.39%

Net Profit Growth

-109.56%

Operating Profit Growth

+54.64%

Dividend Growth

N/A

Stock Returns CAGR

+39.37%
no_data

No Stocks

Smart Score

1.5
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 34.95%

FIIs : 31.49%

DIIs : 14.78%

Public : 18.78%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
DII Shareholding Increased by 0.67% to 14.78% in March 2025 Qtr
FII Shareholding Decreased by 0.19% to 31.49% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Piramal Pharma Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Piramal Pharma Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.

Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan (now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. PPL holds 49% of the paid-up equity share capital in the joint venture. Further, PPL has a minority investment of 33.33% in Yapan Bio that operates in the biologics/ bio-therapeutics and vaccine segments. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Little's, Tetmosol, i-Pill and Polycrol.

Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. It has a global footprint with manufacturing capabilities across 15 facilities spanning across India, US, the UK and Canada. It also has global distribution network in over 100 countries. The Company's global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.

In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).

In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).

In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs.

On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Pharma Limited (PPL), Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to PPL, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of PPL) into PPL; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL was effective from August 18, 2022.

In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022.

In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.

Piramal Pharma Share Price

Piramal Pharma share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Piramal Pharma Market Cap

Market capitalization of Piramal Pharma indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Piramal Pharma is valued compared to its competitors.

Piramal Pharma PE Ratio

Piramal Pharma PE ratio helps investors understand what is the market value of each stock compared to Piramal Pharma 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Piramal Pharma PEG Ratio

The PEG ratio of Piramal Pharma evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Piramal Pharma ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Piramal Pharma generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Piramal Pharma ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Piramal Pharma in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Piramal Pharma Total Debt

Total debt of Piramal Pharma shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Piramal Pharma Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Piramal Pharma compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Piramal Pharma CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Piramal Pharma over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Piramal Pharma Technical Analysis

Technical analysis of Piramal Pharma helps investors get an insight into when they can enter or exit the stock. Key components of Piramal Pharma Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Piramal Pharma shares often struggle to rise above due to selling pressure.

Piramal Pharma Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Piramal Pharma ’s financial health and profitability.

Piramal Pharma Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Piramal Pharma Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Piramal Pharma Financials

The financials of Piramal Pharma provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Piramal Pharma Profit and Loss Statements

The profit and loss statement of Piramal Pharma highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Piramal Pharma .

Piramal Pharma Balance Sheet

The balance sheet presents a snapshot of Piramal Pharma ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Piramal Pharma Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App